Untreated Depressed People Have Fewer Serotonin & Opioid Receptors, And Variation Is Linked To Symptoms And Treatment Response

Posted by poster on August 1st, 2008 under Uncategorized Tags: , ,  •  Comments Off

Depressed people may have far fewer of the receptors for some of the brain’s "feel good" stress-response chemicals than non-depressed people, new University of Michigan Depression Center research shows.
And even among depressed people, the numbers of these receptors can vary greatly. What’s more, the number of receptors a depressed person has appears to be linked with the severity of their symptoms - and the chances that they’ll feel better after taking a medication.
These preliminary findings, presented at the American Psychiatric Association’s annual meeting in Washington, D.C., amplify a growing understanding of depression as a condition that affects different people in different ways, and is solidly rooted in genetic and molecular factors that are unique to each individual.
The lead U-M researcher, Jon-Kar Zubieta, M.D., Ph.D., says these new results bolster what other researchers have been finding in recent years.
"There’s a substantial amount of biological difference even among people who have major depression, which is just as important as the biological differences between people with depression and people without," he says. "The more we can understand about these differences, the better we can address treatment to the individual and have the greatest effect on symptoms."
At the APA meeting, Zubieta presented data from positron emission tomography, or PET, scans of the brains of patients who met the criteria for major depression but had not yet received treatment for it. Those scans were compared with scans of the brains of non-depressed comparison volunteers.
In one group of depressed and non-depressed volunteers, the scans were made using a tracer that can reveal the location and concentration of a particular type of receptor. Called the 5HT1a receptor, it allows brain cells to receive signals from serotonin, a chemical neurotransmitter produced by the brain.
Buy generic viagra Serotonin levels in the brain are linked to depression, but the importance of 5HT1a receptor concentrations in the brains of depressed people has been cloudy. That’s why Zubieta’s team chose to scan only people who had not yet received antidepressant medications, since some such medications may actually encourage the brain’s cells to make more serotonin receptors - and masking the actual level of receptors that the person has naturally.
In the study, 5HT1a receptor concentrations were markedly lower in depressed people compared with non-depressed people, in both the left and right hippocampus region of the brain.
But even among depressed people, the lower a person’s the 5HT1 receptor levels were, the worse he or she scored on assessments of their ability to function day-to-day - and they less likely he or she was to get relief from symptoms when the researchers prescribed them a common antidepressant.
This finding of individual variation may help explain why in current depression treatment, some patients find great relief from a medication that doesn’t help other equally depressed patients, says Zubieta, who is the Phil F. Jenkins Research Professor of Depression in the U-M Department of Psychiatry. He also holds positions in the U-M Nuclear Medicine division, and the Molecular & Behavioral Neuroscience Institute.
The other group of depressed volunteers - both depressed and non-depressed - received PET scans with a tracer that allowed the researchers to see the mu-opioid receptors in their brains. These receptors are the gateway for signals sent by chemicals called endogenous opioids — the brain’s natural "painkillers" - which are involved in stress response including response to pain.
Another name for the neurotransmitters that bind to mu-opioid receptors is endorphins, which have become known as a "feel good" chemical involved in reinforcing rewarding experiences. Illicit drugs such as heroin also act upon mu-opioid receptors, creating the "high" sensation and probably playing a role in the addiction process.
In this group of depressed and non-depressed volunteers, the researchers studied the distribution of the mu-opioid receptors and looked at how active the receptors were when the volunteers were asked to summon a sad memory or scenario to mind.
Depressed volunteers had lower concentrations of mu-opioid receptors to begin with. But when they underwent the "sadness challenge", those receptors were much more active than the receptors in non-depressed people. And, just as with the serotonin 5HT1a receptors, the fewer mu-opioid receptors a person had, the less well they responded to an antidepressant medication.
—————————-
Article adapted by Medical News Today from original press release.
—————————-
Zubieta and his colleagues are now working to submit these new data for publication. At the same time, they are continuing to recruit depressed volunteers who are not taking medication for more brain imaging studies. To find out more about how to participate in depression research at the U-M Depression Center, visit
For more on research by Zubieta and other researchers at the U-M Depression Center, visit
The study was funded by the National Institutes of Health, the Pritzker Foundation, and by NARSAD, a leading mental health charity.
Source: Kara Gavin
University of Michigan Health System
Buy viagra pills | Buy synthroid without prescription | Generic clomid pills no prescription

FDA Approves Cialis(R) (tadalafil) For Once Daily Use For The Treatment Of Erectile Dysfunction

Posted by poster on August 1st, 2008 under Uncategorized Tags: , , , , , , ,  •  Comments Off

Eli Lilly and Company
(Generic propecia pills no prescription NYSE: LLY) announced that the U.S. Food and Drug Administration
(FDA) has approved Cialis(R) (tadalafil)(1) for once daily use (2.5 mg and
5 mg), an oral medication taken once per day to treat erectile dysfunction
(ED). When Cialis for once daily use is taken daily, men can attempt sexual
activity at anytime between doses.
Currently available in parts of Europe, this low-dose daily treatment
option of Cialis may be most appropriate for men with ED who anticipate
more frequent sexual activity (e.g. twice weekly). For other men, Cialis
taken as needed - the previously approved dosing regimen - may be most
appropriate.
In clinical trials, when taken without restrictions on the timing of
sexual activity, Cialis for once daily use improved erectile function over
the course of therapy.
"ED can be a chronic condition like diabetes or high blood pressure,"
said Ridwan Shabsigh, M.D., Director of the Division of Urology at
Maimonides Medical Center in New York. "As a urologist, I know couples like
to have choices and will appreciate the availability of Cialis for once
daily use."
Cialis for use as needed transformed the U.S. ED market when it was
approved in 2003 as the first and only PDE5 inhibitor clinically proven to
provide sustained efficacy for up to 36 hours. Cialis for once daily use
provides a new option for men who may be looking for a dosing option that
can be taken without regard to timing of sexual activity. In consultation
with their physician, patients now have the freedom to choose the dosing
regimen that is appropriate for them.
"We strive to provide patients with solutions that fit their needs and
Cialis for once daily use delivers on this promise," said Shawn Heffern,
Cialis U.S. Director of Brand Marketing at Lilly. "Now, patients have two
options - some may prefer the up to 36 hours of efficacy provided by Cialis
for use as needed while others may want the unique benefit provided by this
daily dosing option."
Additionally, Lilly’s wholesale pricing for Cialis for once daily use
will be comparable to Cialis for use as needed such that patients who
currently use two or more pills per week of Cialis for use as needed should
not experience higher treatment costs with Cialis for once daily use.
The FDA’s approval of Cialis for once daily use was based upon the
evaluation of the comprehensive data package for the daily dosing option.
The data include results from three phase III randomized, double-blind,
placebo- controlled studies. Men with ED who participated in these clinical
studies and who took tadalafil 2.5 mg and 5 mg once daily without regard to
their timing of sexual activity experienced improved erectile function
compared with those taking placebo.(2) Cialis 5 mg, 10 mg and 20 mg have
been approved in the United States for as-needed treatment of ED since
November 2003.
The most commonly reported adverse events were headache, indigestion,
back pain, muscle aches, nasal congestion, flushing and pain in limb. Most
adverse events reported with tadalafil were transient and generally mild or
moderate.
About ED
ED is defined as the consistent inability to attain and maintain an
erection sufficient for sexual intercourse. Experts believe that 80 percent
to 90 percent of ED cases are related to a physical or medical condition,
such as diabetes, cardiovascular diseases, and prostate cancer treatment,
while 10 percent to 20 percent are predominantly due to psychological
causes.(3,4) In many cases, however, both psychological and physical
factors contribute to the condition.(5)
About Cialisz
Cialis(R) (tadalafil) is approved for the treatment of erectile
dysfunction on an as-needed basis or in a daily regimen. The recommended
starting dose of Cialis for use as needed in most patients is 10 mg, taken
prior to anticipated sexual activity. The dose may be increased to 20 mg or
decreased to 5 mg, based on individual efficacy and tolerability. As part
of a daily regimen, Cialis may be taken as 2.5 mg or increased to 5 mg,
based on individual efficacy and tolerability.
Important Safety Information for Cialis
Cialis is available by prescription only and is not for everyone. Men
should discuss their medical conditions and all medications with their
doctors to ensure Cialis is right for them and that they are healthy enough
for sexual
activity. Men taking nitrates, often used for chest pain, should
not take Cialis. Such a combination could cause a sudden, unsafe drop in
blood pressure. Cialis for once daily use provides continuous plasma
tadalafil levels which should be considered when evaluating the potential
for interactions with certain medications (e.g., nitrates, alpha-blockers,
anti- hypertensives and potent inhibitors of CYP3A4) and with substantial
amounts of alcohol. The most common side effects with Cialis were headache,
upset stomach, delayed backache or muscle ache.
As with any ED tablet, in the rare event of priapism (an erection
lasting more than four hours), men should seek immediate medical attention
to avoid long-term injury.
In rare instances, men taking prescription ED tablets (including
Cialis) reported a sudden decrease or loss of vision or hearing (sometimes
with ringing in the ears and dizziness). It’s not possible to determine if
these events are related directly to the ED tablets or to other factors. If
a man has a sudden decrease or loss of vision or hearing, he should stop
taking any ED tablet and seek medical attention right away.
Cialis does not protect a man or his partner from sexually transmitted
diseases, including HIV. Men should not drink alcohol in excess with
Cialis. Individual results may vary. Cialis has not been studied for
multiple attempts per dose.
Individual results may vary. Cialis has not been studied for multiple
attempts per dose. For full patient information and/or full prescribing
information, visit
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own world-wide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Ind., Lilly provides answers - through medicines and
information - for some of the world’s most urgent medical needs. Additional
information about Lilly is available at P-LLY
Certain of the matters discussed herein with respect to clinical
studies and Lilly’s products may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements are based on current expectations,
estimates and projections about the industry, management beliefs and
certain assumptions made by management. Investors are cautioned that
matters subject to forward- looking statements involve risks and
uncertainties, including economic, competitive, governmental, technological
and other factors discussed in the respective filings with the Securities
and Exchange Commission, which may affect the business and prospects of
Lilly. More specifically, there can be no assurance that this product will
achieve commercial success or that competing products will not pre-empt any
market opportunity that might exist for the product.
References
(1) Cialis is a registered trademark of Eli Lilly.
(2) Cialis prescribing information, updated January 2008.
(3) Shabsigh, R. (2002). Back To Great Sex: Overcome ED and Reclaim Lost
Intimacy. New York: Kensington.
(4) Erectile Dysfunction,
Data accessed
09/28/07.
(5) Lue, Tom F. Erectile Dysfunction. N Engl J Med 2000; 342: 1802-1813.
Eli Lilly and Company

View drug information on Cialis.
generic soma online buy | generic cipro online buy | Buy viagra without prescription

New Guidelines For Hypertension Treatment With Diuretics Based On UT Research

Posted by poster on August 1st, 2008 under Uncategorized Tags: , , ,  •  Comments Off

A study based at The University of Texas Health Science Center at Houston provides added justification that a thiazide-type diuretic is the best first-choice drug for hypertensive patients. The findings, published in the American Heart Association’s Circulation, Volume 117, Issue 20, evaluate the results of a previous trial coordinated by researchers at The University of Texas School of Public Health, along with other recent studies.
According to the American Heart Association, about one in three U.S. adults has high blood pressure. Uncontrolled high blood pressure can lead to stroke, heart attack, heart failure or kidney failure. A joint national committee (JNC) on the prevention, detection and evaluation of high blood pressure meets on a regular basis to summarize suggested guidelines for doctors on treating hypertension based on medical research. The study, titled "Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension," analyzes the guidelines of the committee based on previous and recent research.
The findings of the JNC are based on information stemming from a landmark investigation at the UT School of Public Health, which in 2002 established that diuretics were "as good or better" than three other classes of medications for high blood pressure. The original investigation was called ALLHAT - Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
"We found that further analyses of the original ALLHAT trial and information from more recent studies confirmed the original findings that diuretics are the preferred choice for antihypertensive therapy, alone or in combination with other drugs," said Barry Davis, M.D., Ph.D., professor of biostatistics and the director of the Coordinating Center for Clinical Trials at the UT School of Public Health.
"Five years after the ALLHAT results were published, the JNC recommendation still holds," added Davis, who co-authored the study with Jeffrey A. Cutler, M.D., MPH, a consultant to the National Heart, Lung and Blood Institute (NHLBI).
The most recent committee highlighted ALLHAT’s findings in the revision of its guidelines, meaning the information will now be used for practical treatments. Buy soma pills The committee states that when compared to calcium channel blockers, ACE inhibitors and alpha blockers, thiazide-type diuretics are better first-line drug treatments for hypertensive patients. The diuretics excelled in controlling blood pressure, preventing cardiovascular events, are well tolerated by patients and are relatively inexpensive.
Original ALLHAT findings appear in two articles in a 2002 issue of The Journal of the American Medical Association (JAMA). The project consisted of two clinical trials: one compared a diuretic with newer and more expensive antihypertensive drugs to start blood pressure-lowering treatment to ascertain which was best at preventing cardiovascular outcomes; the other compared a statin drug to usual care in lowering cholesterol levels to determine if treatment would lower the occurrence of deaths over the study period. The articles and details of the study and its findings can be found on the study’s web site,
—————————-
Article adapted by Medical News Today from original press release.
—————————-
Source: Natalie Wong Camarata
University of Texas Health Science Center at Houston
generic cialis online buy | Buy soma pills | Buy generic ultram

Adult Stem Cell Therapy For Erectile Dysfunction

Posted by poster on July 30th, 2008 under Uncategorized  •  Comments Off

ORLANDO, FL (UroToday.com) - Dr. Tom Lue discussed autologous stem cell use for ED. He discussed that ability for the planarian species to regenerate any part of its body, but the salamander can only regenerate a limb. In man there are also stem cells, which are undifferentiated cells that have potential to also regenerate.
In adipose tissue there are stem cells as demonstrated by immunohistochemistry, RT-PCR and Western blotting experiments. The adipose derived stem cells (ADSCs) reside near small blood vessels. CD34 staining identifies 60% of peri-vascular areas as harboring ADSCs. It occurs in new blood vessels, and is a sign of regeneration. ADSCs can be harvested by liposuction or fat excision. Adipose cells are digested and ADSCs are cultured for further induction, labeling or gene transfection. ADSCs can also be used for in vivo tissue engineering.
In vitro induction can result in hepatocytes, beta cells to produce insulin or endothelial cells. In vivo, ADSCs placed in muscle can differentiate into skeletal muscle, placed near blood vessels become smooth muscle and in fat can become fat cells. The differentiate into component cell types and integrate into the tissue. Four weeks after injection of ADSCs following cavernous nerve crush injury in a rat model, there is return of function. In older men, he proposed using autologous ADSCs to regenerate erectile function. In rats there is suggestion of differentiation. In a type 2 diabetic rat model of ED, use of ADSCs resulted in improved intracavernosal pressures. Buy generic zithromax He showed neurite cell growth in vitro, that is stimulated by the addition of ADSCs. Experiments using ADSCs to stimulate endothelial cell growth also suggested that this is possible.
A study showed injection of umbilical cord blood stem cells into men having failed PDE5 inhibitors resulted in improved erectile function. This is only a pilot experiment, but shows great promise.
Presented by Tom F. Lue, MD, at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.
Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to:
www.urotoday.com
Copyright © 2008 - UroToday
generic cipro online buy | Generic viagra pills no prescription | Buy ultram pills

Suicide Prevention And Antidepressants

Posted by poster on July 30th, 2008 under Uncategorized Tags: ,  •  Comments Off

Depression is the most important single factor predisposing to suicide, and more than half of all subjects completing suicide are known to have suffered from depression. Unfortunately, depression is still often untreated or undertreated, even after a suicide attempt. Generic clomid pills no prescription Antidepressive drugs represent the cornerstone of treatment of depressive patients. However, their role has become somewhat controversial over the last few years due to reports suggesting that antidepressants might, in a small subgroup of younger patients (recently estimated at 0.7% in clinical trials) actually worsen suicidal tendencies instead of alleviating them.
As a consequence, regulatory authorities in many countries have reconsidered their cost-benefit ratio. On the other hand, in many western countries, increasing use of antidepressants on the national and regional level correlates, as expected with declining suicide mortality, and in no country has an increase in suicides due to antidepressants been reported.
While there is no doubt that potential side effects of antidepressive medication concerning suicidal behaviour are a very serious issue, it is important to obtain a balanced view of all the clinical and epidemiological facts pertaining to the effect of antidepressive therapy in relation to suicidal behaviour.
Professor Erkki Isomets?¤, a renowned expert in psychiatric suicide research, will present the state of evidence and critically comment on the current discussion concerning this topic with regard to the role of antidepressive treatment in real-life clinical practice.
—————————-
Article adapted by Medical News Today from original press release.
—————————-
Press conference on 29 August 2008 in Barcelona, Spain.
SPEAKER: Professor Erkki T. Isomets?¤, Institute of Clinical Medicine, Department of Psychiatry, University of Helsinki, Finland
Source: Sonja Mak
European College of Neuropsychopharmacology
Buy generic viagra | Generic levitra pills no prescription | generic diflucan online buy